Voya Investment Management LLC Cue Biopharma, Inc. Transaction History

Voya Investment Management LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Dec 06, 2024	BUY	$1.77 - $3.09 $23,787 - $41,526	13,439 New	13,439 $25,000
Q1 2024 May 15, 2024	SELL	$1.77 - $3.09 $1,980 - $3,457	-1,119 Reduced 7.69%	13,439 $25,000
Q2 2023 Aug 14, 2023	BUY	$3.11 - $4.91 $45,275 - $71,479	14,558 New	14,558 $53,000
Q2 2022 Aug 15, 2022	SELL	$2.49 - $5.92 $30,509 - $72,537	-12,253 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$10.86 - $17.85 $781 - $1,285	-72 Reduced 0.58%	12,253 $139,000
Q2 2021 Aug 16, 2021	SELL	$10.9 - $14.53 $10,071 - $13,425	-924 Reduced 6.97%	12,325 $144,000
Q1 2021 May 17, 2021	SELL	$11.2 - $16.09 $109,424 - $157,199	-9,770 Reduced 42.44%	13,249 $162,000
Q4 2020 Feb 16, 2021	BUY	$11.12 - $16.4 $38,686 - $57,055	3,479 Added 17.8%	23,019 $288,000
Q3 2020 Nov 16, 2020	BUY	$15.05 - $23.54 $147,038 - $229,985	9,770 Added 100.0%	19,540 $294,000
Q2 2020 Aug 14, 2020	SELL	$12.7 - $30.73 $9,448 - $22,863	-744 Reduced 7.08%	9,770 $239,000
Q4 2019 Feb 14, 2020	BUY	$7.06 - $17.47 $74,228 - $183,679	10,514 New	10,514 $167,000

14.1M

14.4K

2.6K

Ticker CUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,381,700
Market Cap $38.2M
Description
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...

Get notified when there are updates to the investment portfolio of Voya Investment Management LLC, based on Form 13F filings with the SEC.

Stay updated on Voya Investment Management LLC with notifications on news.